BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$83.54 USD
-1.17 (-1.38%)
Updated Jun 21, 2024 09:58 AM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 61 - 80 ( 816 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
ROCTAVIAN Launch Still Grounded in EU; Mar. 31 PDUFA Possibly Delayed; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook: Growth Still Hinges on VOXZOGO and ROCTAVIAN Launches
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
FDA No Longer Holding AdCom is Something for BMRN to be Thankful for
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3: VOXZOGO Beat & Raise but Eyes on ROCTAVIAN EU Launch and FDA AdCom
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
ROCTAVIAN/HemA BLA Accepted; PDUFA Set for March 31, 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Highlights from HemA KOL Call: Gene Therapy''s Role in the Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department